Journal of microbiology, epidemiology and immunobiologyJournal of microbiology, epidemiology and immunobiologyЖурнал микробиологии, эпидемиологии и иммунобиологии0372-93112686-7613Central Research Institute for Epidemiology13627ArticlesСтатьиReview ArticlePNEUMOCOCCAL SURFACE PROTEIN A AND NEW APPROACHES FOR PNEUMOCOCCAL VACCINE DEVELOPMENTПНЕВМОКОККОВЫЙ ПОВЕРХНОСТНЫЙ БЕЛОК А И НОВЫЕ ПОДХОДЫ К РАЗРАБОТКЕ ПНЕВМОКОККОВЫХ ВАКЦИНVorobyevD. SВоробьевД. СSemenovaI. BСеменоваИ. БMechnikov Research Institute ofVaccines and SeraНИИ вакцин и сывороток им. И.И.Мечникова15122011886NO6 (2011)№6 (2011)10711309062023Copyright ©; 2011, Vorobyev D.S., Semenova I.B.Copyright ©; 2011, Воробьев Д.С., Семенова И.Б.2011Vorobyev D.S., Semenova I.B.Воробьев Д.С., Семенова И.Б.https://creativecommons.org/licenses/by/4.0https://microbiol.crie.ru/jour/article/view/13627

The problem of pneumococcal infections is pressing for the whole world. Existing vaccines based only on pneumococci polysaccharide antigens or polysaccharide antigens and diphtherial anatoxin are not capable of protecting from all serotypes of the microorganism. Reasonability of creation of pneumococcal vaccine based on surface proteins of Streptococcus pneumoniae is discussed in the literature. One of such key pneumococcal proteins is pneumococcal surface protein A (PSPA), because it is detected in all the S.pneumoniae strains, has cross activity and switches B-cell immune response to T-cell. Currently the development of conjugated vaccine based on surface proteins and capsule polysaccharides of pneumococcus seems promising.

Проблема пневмококковых инфекций актуальна для всего мира. Существующие вакцины на основе только полисахаридных антигенов пневмококка или полисахаридных антигенов и дифтерийного анатоксина не способны защитить от всех серотипов микроорганизма. В литературе обсуждается целесообразность создания пневмококковой вакцины на основе поверхностных белков Streptococcus pneumoniae. Одним из таких ключевых белков пневмококка является пневмококковый поверхностный белок А (ППБА), т.к. он обнаружен во всех штаммах S. pneumoniae, обладает перекрестной активностью и переключает В-клеточный иммунный ответ на Т-клеточный. В настоящее время перспективной представляется разработка конъюгированной вакцины на основе поверхностных белков и капсульных полисахаридов пневмококка

Streptococcus pneumoniaepneumococcal surface protein Apneumococcal vaccinesпневмококковый поверхностный белок Апневмококковые вакциныБрико Н.И. Распространенность и возможности профилактики пневмококковых инфекций в мире и в России. Вакцинация. 2009, 2 (58): 5-7.Воробьев Д.С., Семенова И.Б., Курбатова Е.А. Белки Streptococcus pneumoniae: перспективы создания вакцины против пневмококковой инфекции. Журн. микробиол. 2010, 6: 98104.Пилипенко В.В. Пневмококковые менингиты у взрослых: необходимость профилактической вакцинации после 45 лет. Эпидемиол. вакцинопроф. 2010, 6 (55): 63-67.Ряпис Л.А., Брико Н.И. Эпидемиологический надзор и тактика специфической профилактики инвазивных пневмококковых инфекций в России. Журн. микробиол. 2009, 6: 112-118.Таточенко В.К. Перспективы развития иммунопрофилактики в России. Журн. микробиол. 2010, 5: 90-98.Briles D.E., King J.D., Gray M.A. et al. PspA, a protection-eliciting pneumococcal protein: immunogenicity of isolated native PspA in mice. Vaccine. 1996, 14 (9): 858-867.Calbo E., Garau J. Of mice and men: innate immunity in pneumococcal pneumonia. Intern. J. Antimicrob. Agents. 2010, 35: 107-113.Casado-Flores J., Rodrigo C., Aristegui J. et al. Decline in pneumococcal meningitis in Spain after introduction of the heptavalent pneumococcal conjugate vaccine. Pediatr. Infect. Dis. 2008, 27 (11): 10201022.Darrieux M., Miyaji E.N., Ferreira D.M. et al. Fusion proteins containing family 1 and family 2 PspA fragments elicit protection against Streptococcus pneumoniae that correlates with antibody-mediated enhancement of complement deposition. Infect. Immun. 2007, 75 (12): 59305938.Devineni D., Paulos S., Ubale R. et al. Approaches and issues towards development of efficient mucosal vaccines against pneumonia. Clin. Res. Regul. Affairs. 2009, 26 (3): 39-49.Ferreira D.M., Darrieux M., Silva D.A. et al. Characterization of protective mucosal and systemic immune responses elicited by pneumococcal surface protein A PspA and PspC nasal vaccines against a respiratory pneumococcal challenge in mice. Clin. Vac. Immunol. 2009, 16 (5): 636-645.Harboe Z.B., Thomsen R.W, Riis A. et al. Pneumococcal serotypes and mortality following invasive pneumococcal disease: a population-based cohort study. PLoS Med. 2009, 6 (5): 1-13.Hicks L.A., Harrison L.H., Flannery B. et al. Incidence ofpneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era ofwidespread PCV7 vaccination, 1998-2004. J. Infect. Dis. 2007,196: 1346-1354.Hollingshead S.K., Baril L., Ferro S. et al. Pneumococcal surface protein A (PspA) family distribution among clinical isolates from adults over 50 years of age collected in seven countries. J. Med. Microbiol. 2006, 55: 215-221.Hsieh Y-C., Lee W-S., Shao P-L. et al. The transforming Streptococcus pneumoniae in the 21st century. Chang. Gung. Med. J. 2008, 31: 117-124.Jansen A.G., Rodenburg G.D., van der Ende A. et al. Invasive pneumococcal disease among adults: associations among serotypes, disease characteristics, and outcome. Clin. Infect. Dis. 2009, 49 (2): 23-29.Jedrzejas M.J. Pneumococcal virulence factors: structure and function. Microbiol. Mol. Biol. 2001, 65 (2): 187-207.Kang H.Y., Srinivasan J., Curtiss R. Immune responses to recombinant pneumococcal PspA antigen delivered by live attenuated Salmonella enterica Serovar Typhimurium vaccine. Infect. Immun. 2002, 70 (4): 1739-1749.Lu Y-J., Forte S., Thompson C.M. et al. Protection against pneumococcal colonization and fatal pneumonia by a trivalent conjugate of a fusion protein with the cell wall polysaccharide. Infect. Immun. 2009, 77 (5): 2076-2083.Madhi S.A., Levine O.S., Hajjeh R. et al. Vaccines to prevent pneumonia and improve child survival. Bull. WHO. 2008, 86 (5): 365-372.McDaniel L.S., Ralph B.A., McDaniel D.O. et al. Localization of protection-eliciting epitopes on PspA ofStreptococcus pneumoniae between amino acid residues 192 and 260. Microb. Pathog. 1994, 17: 323-337.McDaniel L.S., Sheffield J.S., Delucchi P. et al. PspA, a surface protein of Streptococcus pneumoniae, is capable of eliciting protection against pneumococci of more than capsular type. Infect. Immun. 1991, 59: 222-228.McDaniel L.S., Yother J., Vijayakumar M. et al. Use of insertional inactivation to facilitate studies of biological properties of pneumococcal surface protein A (PspA). J. Exp. Med. 1987, 165 (2): 381394.Melin M.M., Hollingshead S.K., Briles D.E. et al. Distribution ofpneumococcal surface protein A families 1 and 2 among Streptococcus pneumoniae isolates from children in Finland who had acute otitis media or were nasopharyngeal carriers. Clin. Vac. Immunol. 2008, 15 (10): 15551563.Meng C., Lin H., Huang J. et al. Development of 5-valent conjugate pneumococcal protein A - capsular polysaccharide pneumococcal vaccine against invasive pneumococcal disease. Microb. Pathog. 2009, 47: 151-156.Moreno A.T., Oliveira M.L., Ferreira D.M. et al. Immunization of mice with single PspA fragments induces antibodies capable ofmediating complement deposition on different pneumococcal strains and cross-protection. Clin. Vac. Immunol. 2010, 17 (3): 439-446.Nabors G.S., Braun P.A., Herrmann D.J. et al. Immunization ofhealthy adults with a single recombinant pneumococcal surface protein A (PspA) variant stimulates broadly cross-reactive antibodies to heterologous PspA molecules. Vaccine. 2000,18: 1743-1754.Ogunniyi A.D., Grabowicz M., Briles D.E. et al. Development of a vaccine against invasive pneumococcal disease based on combinations of virulence proteins of Streptococcus pneumoniae. Infect. Immun. 2007, 75 (1): 350-357.Oliveira M.L., Miyaji E.N., Ferreira D.M. et al. Combination ofpneumococcal surface protein A (PspA) with whole cell pertussis vaccine increases protection against pneumococcal challenge in mice. PLoS One. 2010, 5 (5): e10863.Ortqvist A. Pneumococcal vaccination: current and future issues. Eur. Respir. J. 2001, 18: 184-195.Paton J.C. Novel pneumococcal surface proteins: role in virulence and vaccine potential. Trends Microbiol. 1998, 6 (3): 85-88.Rajam G., Anderton J.M., Carlone G.M. et al. Pneumococcal surface adhesion A (PsaA): a review. Crit. Rev. Microbiol. 2008,34: 131-142.Rappuoli R. Bridging the knowledge gaps in vaccine design. Nature Biotechnology. 2007, 25 (12): 1361-1366.Roche H., Hakansson A., Hollingshead S.K., Briles D.E. Regions of PspA/ EF3296 best able to elicit protection against Streptococcus pneumoniae in a murine infection model. Infect. Immun. 2003, 71 (3): 1033-1041.Schenkein J.G., Nahm M.H., Dransfield M.T. Pneumococcal vaccination for patients with COPD: current practice and future directions. Chest. 2008, 133 (3): 767-774.Shoma S., Verkaik N.J., de Vogel C.P. et al. Development of a multiplexed bead-based immunoassay for the simultaneous detection ofantibodies to 17 pneumococcal proteins. Eur. J. Clin. Microbiol. Infect. Dis. 2011, 30: 521-526.Tai S.S. Streptococcus pneumoniae protein vaccine candidates: properties, activities and animal studies. Critical Rev. Microbiol. 2006, 32: 139-153.Talkington D.F., Crimmins D.L., Voellinger D.C. et al. A 43-kilodalton pneumococcal surface protein, PspA: isolation, protective abilities, and structural analysis ofthe amino-terminal sequence. Infect. Immun. 1991, 59: 1285-1289.Targonski P.V., Poland G.A. Pneumococcal vaccination in adults: recommendations, trends, and prospects. Cleve. Clin. J. Med. 2007, 74 (6): 401-414.Worldwide progress in introducing pneumococcal conjugate vaccine, 2000 - 2008. WHO Weekly Epidemiol. Rec. 2008, 83 (43): 388-392.Yother J., Briles D.E. Structural properties and evolutionary of PspA, a surface protein of Streptococcus pneumoniae, as revealed by sequence analysis. J. Bacteriology. 1992, 174 (2): 601-609.Yother J., White J.M. Novel surface attachment mechanism of the Streptococcus pneumoniae protein PspA. J. Bacteriology. 1994, 176 (10): 2976-2985.Zhang Z., Clarke T.B., Weiser J.N. Cellular effectors mediating Th17-dependent clearance of pneumococcal colonization in mice. J. Clin. Invest. 2009, 119 (7): 1899-1909.